Ubiquinol
Alternative Names: NPC-29Latest Information Update: 12 Sep 2024
Price :
$50 *
At a glance
- Originator Nobelpharma
- Class Alcohols; Antineoplastics; Benzoquinones; Cardiotonics; Coenzymes; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Multiple system atrophy
Most Recent Events
- 07 Aug 2024 Phase-II clinical trials in Multiple system atrophy in Japan (unspecified route) (Nobelpharma pipeline, August 2024)
- 07 Aug 2024 Nobelpharma plans a phase III trial for Multiple system atrophy in September 2024 (Nobelpharma pipeline, August 2024)